Magnetic–Acoustic Sequentially Actuated CAR T Cell Microrobots for Precision Navigation and In Situ Antitumor Immunoactivation
Sign Up to like & getrecommendations! Published in 2023 at "Advanced Materials"
DOI: 10.1002/adma.202211509
Abstract: Despite its clinical success, chimeric antigen receptor T (CAR T)‐cell immunotherapy remains limited in solid tumors, owing to the harsh physical barriers and immunosuppressive microenvironment. Here a CAR‐T‐cell‐based live microrobot (M‐CAR T) is created by… read more here.
Keywords: cell; antitumor; car; magnetic acoustic ... See more keywords
An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Hematology"
DOI: 10.1002/ajh.25418
Abstract: Chimeric antigen receptor (CAR) T‐cell therapy represents a major advancement in personalized cancer treatment. In this strategy, a patient's own T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen.… read more here.
Keywords: car cell; antigen; receptor; cancer ... See more keywords
Changes to culture pH and dissolved oxygen can enhance chimeric antigen receptor T‐cell generation and differentiation
Sign Up to like & getrecommendations! Published in 2022 at "Biotechnology Progress"
DOI: 10.1002/btpr.3275
Abstract: Chimeric antigen receptor (CAR) T‐cell therapy is growing clinically and commercially as a powerful new approach to treat cancer. Understanding how key culture conditions such as pH and dissolved oxygen (DO) affect CAR T‐cell generation… read more here.
Keywords: culture; cell; cell generation; car ... See more keywords
Light‐Controllable Binary Switch Activation of CAR T Cells
Sign Up to like & getrecommendations! Published in 2022 at "Chemmedchem"
DOI: 10.1002/cmdc.202100722
Abstract: Major challenges to chimeric antigen receptor (CAR) T cell therapies include uncontrolled immune activity, off‐tumor toxicities and tumor heterogeneity. To overcome these challenges, we engineered CARs directed against small molecules. By conjugating the same small… read more here.
Keywords: cell; tumor; car; car cell ... See more keywords
Top advances in lymphoma for 2021
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34483
Abstract: Chimeric antigen receptor (CAR) T‐cell therapy, antibody–drug conjugates, bispecific T‐cell redirectors, and agents targeting tonic B‐cell receptor signaling have altered the paradigm for three of the most common lymphomas in the year 2021. For diffuse… read more here.
Keywords: cell; top advances; lymphoma; advances lymphoma ... See more keywords
Microraft arrays for serial‐killer CD19 chimeric antigen receptor T cells and single cell isolation
Sign Up to like & getrecommendations! Published in 2022 at "Cytometry Part A"
DOI: 10.1002/cyto.a.24678
Abstract: Chimeric antigen receptor T (CAR‐T) cell immunotherapies have seen success in treating hematological malignancies in recent years; however, the results can be highly variable. Single cell heterogeneity plays a key role in the variable efficacy… read more here.
Keywords: cell; antigen receptor; microraft; chimeric antigen ... See more keywords
SAFETY AND CLINICAL ACTIVITY OF RP6530, A DUAL PI3Kδ/γ INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES: FINAL ANALYSIS OF A PHASE 1 MULTI‐CENTER STUDY
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2438_133
Abstract: patients were analyzed by flow cytometry and modeled against CAR T cell levels. In vivo CAR T‐cell levels were measured by qPCR. T‐cell expansion during production (fold expansion/total days in culture) was compared with CAR… read more here.
Keywords: car cell; expansion; analysis; axi cel ... See more keywords
Overcoming resistance to anti‐CD19 CAR T‐cell therapy in B‐cell malignancies
Sign Up to like & getrecommendations! Published in 2022 at "Hematological Oncology"
DOI: 10.1002/hon.3036
Abstract: Anti‐CD19 chimeric antigen receptor (CAR) T‐cell therapy has rapidly changed current treatment pattern, providing a better option for individuals with primary refractory or relapsed B‐cell non‐Hodgkin lymphoma (r/r B‐NHL) and B‐cell acute lymphoblastic leukemia (r/r… read more here.
Keywords: cell; cd19; cell therapy; car ... See more keywords
A unique hub‐and‐spoke model to optimize patient management in lymphoma using novel CAR‐T cell therapy in Southeast and South Asia
Sign Up to like & getrecommendations! Published in 2022 at "Hematological Oncology"
DOI: 10.1002/hon.3065
Abstract: Novel therapeutic options for cancer offer hope for patients and their families, particularly when the cancer has not responded to established treatment regimens. The CAR‐T cell therapeutic approach has changed the treatment paradigm for relapsed… read more here.
Keywords: lymphoma; car; southeast south; car cell ... See more keywords
Reply to: Comments on “Cost of decentralized CAR T cell production in an academic non‐profit setting”
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Cancer"
DOI: 10.1002/ijc.33253
Abstract: Dear Editors, We have read with interest the comments by Schmitt et al to our study of the “cost of decentralized CAR T-cell production in an academic setting.” While the letter confirms the sensitivity of… read more here.
Keywords: cell production; car cell; cost; production ... See more keywords
Lack of defined apheresis collection criteria in publicly available CAR-T cell clinical trial descriptions: Comprehensive review of over 600 studies.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of clinical apheresis"
DOI: 10.1002/jca.21964
Abstract: BACKGROUND Chimeric antigen receptor T (CAR-T) cell successes have encouraged continued clinical study. Apheresis collection of starting material for CAR-T cell therapy product manufacturing is critical but described approaches suggest variability and clinical guidelines are… read more here.
Keywords: apheresis collection; apheresis; car cell; cell ... See more keywords